Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) Equity Average (2016 - 2025)

Ptc Therapeutics (PTCT) has 13 years of Equity Average data on record, last reported at -$180.5 million in Q4 2025.

  • For Q4 2025, Equity Average rose 83.22% year-over-year to -$180.5 million; the TTM value through Dec 2025 reached -$180.5 million, up 83.22%, while the annual FY2025 figure was -$651.7 million, 32.0% up from the prior year.
  • Equity Average reached -$180.5 million in Q4 2025 per PTCT's latest filing, roughly flat from -$181.2 million in the prior quarter.
  • Across five years, Equity Average topped out at $387.3 million in Q1 2021 and bottomed at -$1.1 billion in Q4 2024.
  • Average Equity Average over 5 years is -$360.7 million, with a median of -$245.8 million recorded in 2022.
  • Peak YoY movement for Equity Average: plummeted 802.65% in 2023, then skyrocketed 83.22% in 2025.
  • A 5-year view of Equity Average shows it stood at $53.2 million in 2021, then plummeted by 639.65% to -$287.0 million in 2022, then crashed by 159.48% to -$744.7 million in 2023, then crashed by 44.52% to -$1.1 billion in 2024, then surged by 83.22% to -$180.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were -$180.5 million in Q4 2025, -$181.2 million in Q3 2025, and -$196.2 million in Q2 2025.